The estimated Net Worth of Alicia Secor is at least $1.47 Milion dollars as of 1 March 2021. Ms. Secor owns over 3,144 units of GW Pharmaceuticals stock worth over $829 and over the last 10 years she sold GWPH stock worth over $1,114,500. In addition, she makes $355,323 as Non-Executive Independent Director at GW Pharmaceuticals.
Sign up
Ms. Secor GWPH stock SEC Form 4 insiders trading
Alicia has made over 9 trades of the GW Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 3,144 units of GWPH stock worth $220 on 1 March 2021.
The largest trade she's ever made was selling 26,256 units of GW Pharmaceuticals stock on 17 September 2015 worth over $1,077,809. On average, Alicia trades about 1,700 units every 84 days since 2014. As of 1 March 2021 she still owns at least 11,844 units of GW Pharmaceuticals stock.
You can see the complete history of Ms. Secor stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alicia Secor biography
Alicia Secor serves as Non-Executive Independent Director of the Company. Ms. Secor brings more than 25 years of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas. Ms. Secor is President and Chief Executive Officer of Atalanta Therapeutics, Inc., a biotechnology company. She is a member of the board of directors, the compensation committee and nominating and governance committee of Orchard Therapeutics plc, a biopharmaceutical company. Previously, she served as President and Chief Executive Officer of Juniper Pharmaceuticals, Inc., a Nasdaq listed pharmaceutical company from August 2016 until August 2018, the date the company was acquired by Catalent, Inc. From January 2014 to July 2016, she served as the chief commercial officer of Zafgen Inc., a biopharmaceutical company. From August 2013 to October 2013, she served as senior vice president and chief operating officer of Synageva BioPharma Corp., a biotechnology company. Previously, from November 1998 to July 2013, Ms. Secor spent 15 years at Genzyme, a biotechnology company, where she held various leadership positions, most recently as vice president and general manager of Metabolic Diseases, a global business with five marketed products, including two products for orphan diseases. Prior to this role, she was vice president and general manager of Biosurgical Specialties, a surgical device business focused on adhesion prevention and other novel applications for biomaterials. Prior to Genzyme, Ms. Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. (a Johnson & Johnson company) in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative. Ms. Secor also serves as a member of the board of directors for the Foundation for Prader Willi Research.
What is the salary of Alicia Secor?
As the Non-Executive Independent Director of GW Pharmaceuticals, the total compensation of Alicia Secor at GW Pharmaceuticals is $355,323. There are 10 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is Alicia Secor?
Alicia Secor is 57, she's been the Non-Executive Independent Director of GW Pharmaceuticals since 2017. There are 6 older and 7 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Alicia Secor's mailing address?
Alicia's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble oraz Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Ms. Secor stock trades at G1 Therapeutics Inc, GW Pharmaceuticals, Zafgen oraz Orchard Therapeutics plc
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America